非酒精性脂肪性肝病与肝硬化

doi:10.3969/j.issn.1672-5069.2016.02.003

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (2): 135-138.doi: 10.3969/j.issn.1672-5069.2016.02.003

非酒精性脂肪性肝病与肝硬化

马振增, 陆伦根

200080上海市交通大学附属第一人民医院消化科

收稿日期:2016-01-01 出版日期:2016-03-10 发布日期:2016-03-04
通讯作者: 陆伦根,E-mai:lungenlun1965@163.com
作者简介:马振增,男,36岁,博士研究生,主治医师。主要从事肝纤维化的发病机制研究。E-mail:mazhenzeng1979@163.com.

Nonalcoholic fatty liver disease and liver cirrhosis

Ma Zhenzeng, Lu Lungen

Department of Gastroenterology,Shanghai General Hospital,JiaoTong University School of Medicine , Shanghai 200080, China

Received:2016-01-01 Online:2016-03-10 Published:2016-03-04

摘要/Abstract

摘要： 非酒精性脂肪性肝病（Nonalcoholic fatty liver disease, NAFLD）发病与胰岛素抵抗（Insulin resistance, IR）和遗传易感性密切相关,病理学改变与酒精性肝病（Alcoholic liver disease, ALD）相似,但无过量饮酒史^[1]。在此要强调NAFL与NASH的不同,NAFL是指病理活检显示肝脏脂肪变性,但是不具有肝纤维化或气球样变性的肝细胞损伤。NASH指在肝脏脂肪变基础上出现气球样肝细胞损伤伴或不伴肝纤维化^[2],NASH发生肝纤维化、肝硬化、肝细胞癌风险明显增高,而NAFL则很低^[2],NASH是NAFL发生肝硬化的必经阶段^[3]。

关键词: 非酒精性脂肪性肝病, 肝硬化, 自然史, 流行病学, 评估, 治疗

Key words: Nonalcoholic fatty liver disease, Liver cirrhosis, Natural history, Epidemiology, Evaluation, Treatment

马振增, 陆伦根. 非酒精性脂肪性肝病与肝硬化[J]. 实用肝脏病杂志, 2016, 19(2): 135-138.

Ma Zhenzeng, Lu Lungen. Nonalcoholic fatty liver disease and liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 135-138.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南.中国医学前沿杂志（电子版）, 2012, 4（7）:4-10.
[2] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fattyliver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther ,2011, 34:274-285.
[3] de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol, 2008, 48 （Suppl 1）:5104-5112.
[4] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:The major impact of China.Hepatology, 2014, 60:2099-2108.
[5] Amarapurkar DN, Hashimoto E, Lesmana LA, et al. Asia-Pacific Working Party for NAFLD. Howcommon is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences J Gastroenterol Hepatol, 2007,22:788-793.
[6] Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 2004, 40:185-194.
[7] Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol, 2012, 47:215-225.
[8] Chalasani N, Zobair Younossi F, Joel E. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55（6）：2005-2023.
[9] Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
[10] Musso G, Gambino R, Cassader M,et al. Meta-analysis:natural history of non-alcoholic fatty liver disease （NAFLD）and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med , 2011, 43: 617-649.
[11] Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up ofpatients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44: 865-873.
[12] White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol, 2012, 10: 1342-1359.
[13] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol, 2013, 10:656-665.
[14] Agrawal S, Duseja AK. Non-alcoholic fatty liver disease: East versus west. J Clin Experiment Hepatol, 2012, 2 （2）: 122-134.
[15] Nayak NC, Vasdev N, Saigal S, et al. End-stage nonalcoholicfatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol, 2010, 41:425-430.
[16] Michitaka K, Nishiguchi S, Aoyagi Y, et al.Japan etiology of liver cirrhosis study group. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol, 2010, 45:86-94.
[17] Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol, 2014, 28 : 637-653.
[18] Vlad R, Stefano B, Helena H. CA position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol , 2010 ,53 :372-384.
[19] Jessica KD, Quentin MA, Stuart MP. Non-alcoholic fatty liver disease:a practical approach to diagnosis and staging. Frontl Gastroenterol, 2014, 5:211-218.
[20] Schwenzer NF, Springer F, Schraml C, et al. Non-invasiveassessment and quantification of liver steatosis by ultrasound,computed tomography and magnetic resonance. J Hepatol,2009, 51:433-445.
[21] Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosisscore: a noninvasive system that identifies liver fibrosis inpatients with NAFLD. Hepatology, 2007, 45:847-854.
[22] Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosisand cirrhosis using liver stiffness measurement in nonalcoholicfatty liver disease. Hepatology, 2010,51:454-462.
[23] Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liverdisease: US-based acoustic radiation force impulse elastography.Radiology,2010,256:640-647.
[24] Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology, 2008,47:455-460.
[25] Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44:27-33.

非酒精性脂肪性肝病与肝硬化

Nonalcoholic fatty liver disease and liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[3]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[4]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[5]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[6]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[7]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[8]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[9]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[10]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[11]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[12]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[13]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[14]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[15]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.